Enantioselective determination of cetirizine in human urine by HPLC

Abstract

In order to study the simultaneous determination of (+)- and (−)-cetirizine in human urine we have developed a chiral separation method by HPLC. A chiral stationary phase of α₁-acidglycoprotein, the AGP-CSP, was used to separate the enantiomers. The pH of the phosphate buffer, as well as the content of the organic modifier in the mobile phase, markedly affected the chromatographic separation of (+)- and (−)-cetirizine. A mobile phase of 10 mmol/l phosphate buffer (pH 7.0)-acetonitrile (95∶5, v/v) was used for the urine assays. Ultraviolet absorption was monitored at 230nm and roxatidine was employed as the internal standard for quantification.

(+)-Cetirizine, (−)-cetirizine and the internal standard were eluted at retention times of 12, 16, and 32 mins, respectively. The detection limit for cetirizine enantiomers was 400 ng/ml of urine. A pharmacokinetic study was conducted with the help of 5 healthy female volunteers who were administered with a single oral dose of racemic cetirizine (20 mg). The peak area ratios provided by the cetirizine enantiomers were linear(r>0.997) over a concentration range of 2.5-200 μg/ml. The peak of the excreted cetirizine enantiomers appeared in the urine sample during the period of 1–2 hrs following the administration of the oral dose. The excreted level of (+)-cetirizine was slightly higher than (−)-cetirizine but the difference was not statistically significant. However, this method appears to have applications for enantioselective pharmacokinetic studies of racemic drugs.